ria

Tejaswi

@tejaswi.2054
Indore
12+ Years of experience
SEBI Registration INA200015176
I'm Tejaswi, and I lead Equity Nest, an Indore-based community dedicated to simplifying investment strategies and empowering people with financial knowledge. Through clear, data-driven insights, I make financial planning, investment analysis and mutual fund strategies accessible to everyone, guiding members toward fina ... Read more
Trade Ideas
453
Opinions
1k
Followers
115k

Expertise

Quantitative
Growth
Technical
Index Strategies
Swing Trading
Market Commentary
Futures & Options
Technical Analysis
Trade Facts
Total Trades
0
Missed Trades
0
Profit Trades
0
icon0%
Accuracy
Ask me Anything

Got a question? Ask me and I will answer it. Stay curious, stay hungry!

Posts

shared an insight ⚡️ 10 hours ago
Poly Medicure: PAT Growth Lags at 3.6% on Margin Pressure
POLYMED Poly Medicure (NSE : POLYMED) manufactures finished medical devices across infusion therapy, renal care and cardiology. Its product range covers IV cannulas, needle-free connectors, dialysis machines, drug-eluting stents and cardiovascular catheters. It operates 15 plants across five countries with annual production capacity of 1.9 billion units. What happened: In Q2 FY27, revenue grew 30.8% year on year to Rs 580.5 crore. EBITDA rose 20.1% to Rs 139.1 crore, with margin at 24%, down 210 basis points. PAT grew only 3.6% to Rs 95.1 crore. International markets contributed 71% of H1 FY27 revenue. The company added 30 international customers in H1 and commenced first dispatches from its Brazilian subsidiary in October. Why it matters: Revenue is growing but earnings are not keeping pace. Acquisitions, overseas establishment costs and higher freight expenses are compressing margins. The company has filed an anti-dumping case against Chinese dialysis equipment imports. It is targeting a doubling of revenue by FY30, with FY27 capex guidance of Rs 200 to 225 crore. What I am watching: Whether margin recovery follows revenue expansion. The cash conversion cycle edged up to 136 days from 135, and inventory days rose to 73 from 70. The cardiology portfolio, including drug-eluting stents, is at an early clinical stage and needs to demonstrate repeat commercial demand beyond initial launches. My stance: Poly Medicure trades at approximately 54 times earnings and has declined 12% over the past year. ROCE is 12.5% and ROE is 9.8%. The revenue trajectory is strong, but the valuation requires earnings to recover alongside expansion. That recovery is not yet visible in the numbers. I do not hold a position in Poly Medicure at the time of writing. This is not investment advice.
shared an insight ⚡️ 21st Nov
Data Patterns: BrahMos Seeker Awaiting Qualification
DATAPATTNS Data Patterns (NSE : DATAPATTERNS) develops high-end indigenous defence electronics with proprietary intellectual property. The company built the BrahMos fire-control system in 2001 and has since designed an indigenous BrahMos seeker, currently undergoing qualification testing before production orders can be placed. What happened: In Q2 FY27, revenue fell 56.7% year on year to Rs 133.2 crore, against a high base when a large multi-year radar contract was executed. Operating profit fell 54.1% to Rs 31.4 crore, though margin expanded 132 basis points to 23.6%. Net profit halved to Rs 22 crore. The order book reached Rs 1,742 crore as of November 9, 2026, up from Rs 927 crore on April 1, 2026. Why it matters: Negotiated orders awaiting formal contracts total Rs 956 crore, all in approved programmes with no cancellation risk per management. Additional FY27 order inflows of Rs 1,500 to 2,000 crore are expected before March 2027. The medium-term pipeline is estimated at Rs 2,000 to 4,000 crore. Management guides for 20% to 25% revenue growth and 35% to 40% EBITDA margins in FY27. What I am watching: When qualification testing for the BrahMos seeker concludes and a production order follows. Data Patterns is pre-stocking inventory for immediate delivery post-qualification. The seeker represents 20% to 30% of a missile’s unit cost, making it the highest-value single component in a guided weapon. My stance: Data Patterns trades at 95 times earnings, above its five-year median of 72.9 times and the industry median. ROCE is 21.9% and ROE is 15.9%. The valuation reflects expected seeker revenue that has not materialised yet. Qualification outcome and order timing are the key variables. I do not hold a position in Data Patterns at the time of writing. This is not investment advice.
shared an insight ⚡️ 20th Nov
Kaynes Technology: PAT Down 53% on Higher Costs
KAYNES Kaynes Technology (NSE : KAYNES) is an end-to-end IoT-enabled electronics system and design manufacturer. It serves automotive, industrial, EV, aerospace, medical, railways and strategic electronics customers across 16 manufacturing facilities, with service centres in Cochin and Mumbai. What happened: In H1 FY27, revenue grew 18% year on year to Rs 18,987 million. EBITDA rose 3% to Rs 2,681 million, with margin contracting 200 basis points. PAT fell 53% to Rs 852 million due to higher costs. The order book stood at Rs 106,252 million as of September 30, 2026, up 31% year on year from Rs 80,994 million a year earlier. Why it matters: The company formed a joint venture, Toyokawa Techno Private Limited, with 90% Kaynes stake, to manufacture TFT display modules, FOG/COG bonding and optical bonding solutions for automotive and industrial customers. The Indian EMS market is forecast to grow from US$ 40 billion to US$ 150 billion by FY30, a 30% CAGR per KPMG. What I am watching: Whether the cost pressures that caused the 53% PAT decline are temporary or structural. Revenue growth of 18% and order book growth of 31% show demand is intact, but the EBITDA margin compression and sharp profit fall suggest execution costs are rising faster than revenue. The JV investment details and revenue timelines have not yet been disclosed. My stance: The stock has fallen more than 50% over the past year, trading at Rs 2,908 against a 52-week high of Rs 6,347. The order book of Rs 106,252 million provides strong multi-year revenue cover. However, the PAT decline raises questions about near-term earnings quality that need monitoring before any conclusion. I do not hold a position in Kaynes Technology at the time of writing. This is not investment advice.

FAQ's

What are the top stock recommendations by Tejaswi?

up
Tejaswi regularly shares stock views and market analysis on StockGro. Some of the stocks they have recently shared views on include Asahi India Glass Ltd. (Bullish), POLYMED, DATAPATTNS and KAYNES. Explore Tejaswi's complete list of posts and trade views on their StockGro profile.

How can I follow Tejaswi's latest investment insights?

up
You can follow Tejaswi's latest investment insights, stock recommendations, and market analysis on StockGro App. Additionally, you can check their detailed stock analysis reports in the StockGro blog section.

What is Tejaswi's investment strategy?

up
Tejaswi follows a data-driven, research-backed investment strategy focused on maximizing returns while managing risk. Their approach includes fundamental and technical analysis, portfolio diversification, and sectoral trends to identify high-potential stocks.

How long has Tejaswi been a SEBI-registered Research Analyst (RA)?

up
Tejaswi has been a SEBI-registered Research Analyst and have 12+ Years of experience. With extensive experience in stock market analysis and investment research, they have guided investors in making informed and profitable decisions.

Where can I see Tejaswi's past performance and stock picks?

up
You can check Tejaswi's past stock recommendations, success rate, and investment insights on their StockGro profile. Their historical stock picks reflect a track record of strategic investment decisions based on thorough research.

How can I contact Tejaswi for stock market advice?

up
For stock market guidance from Tejaswi, you can connect through their StockGro profile. Some RAs may also provide personalized investment consultations based on their availability and SEBI regulations.

What is Tejaswi's track record in predicting market movements?

up
Tejaswi has a proven track record of accurate market analysis and trend predictions. By analyzing economic indicators, market sentiment, and technical charts, they have consistently helped investors make well-timed investment decisions.

What is the SEBI Registration number for Tejaswi?

up
Tejaswi is a SEBI-registered Research Analyst with the SEBI Registration INA200015176. This ensures that their investment recommendations comply with SEBI's regulatory framework for investor protection and financial advisory standards.
Be Financially Free with StockGro